Carmofur
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Carmofur (INN) or HCFU (1-hexylcarbamoyl-5-fluorouracil) is a pyrimidine analogue used as an antineoplastic agent. It is a derivative of fluorouracil.
Uses
Breast Cancer
Colorectal Cancer
Carmofur, in its oral form, has also been used as adjuvant chemotherapy for curatively resected colorectal cancer patients. Trials and meta-analyses have confirmed that the drug is effective on patients with this cancer type, extending their survival.[1]
Adverse effects
As fluorouracil, carmofur has been known to induce leukoencephalopathy.[2][3][4]
References
- ↑ Sakamoto, J; Hamada, C; Rahman, M; Kodaira, S; Ito, K; Nakazato, H; Ohashi, Y; Yasutomi, M (2005). “An Individual Patient Data Meta-analysis of Adjuvant Therapy with Carmofur in Patients with Curatively Resected Colon Cancer”. Japanese Journal of Clinical Oncology. 35 (9): 536–544. doi:10.1093/jjco/hyi147. PMID 16155120.
- ↑ Yamada T, Okamura S, Okazaki T; et al. (June 1989). “Leukoencephalopathy following treatment with carmofur: a case report and review of the Japanese literature”. Asia Oceania J Obstet Gynaecol. 15 (2): 161–8. PMID 2667512.
- ↑ Mizutani T (February 2008). “[Leukoencephalopathy caused by antineoplastic drugs]”. Brain Nerve (in Japanese). 60 (2): 137–41. PMID 18306661.
- ↑ Baehring JM, Fulbright RK (May 2008). “Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients”. J Neurol Neurosurg Psychiatr. 79 (5): 535–9. doi:10.1136/jnnp.2007.123737. PMID 17682013.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
